PT  - JOURNAL ARTICLE
AU  - J. Cory Kalvass
AU  - Emily R. Olson
AU  - Gary M. Pollack
TI  - Pharmacokinetics and Pharmacodynamics of Alfentanil in P-Glycoprotein-Competent and P-Glycoprotein-Deficient Mice: P-Glycoprotein Efflux Alters Alfentanil Brain Disposition and Antinociception
AID  - 10.1124/dmd.106.011445
DP  - 2007 Mar 01
TA  - Drug Metabolism and Disposition
PG  - 455--459
VI  - 35
IP  - 3
4099  - http://dmd.aspetjournals.org/content/35/3/455.short
4100  - http://dmd.aspetjournals.org/content/35/3/455.full
SO  - Drug Metab Dispos2007 Mar 01; 35
AB  - Previous studies have indicated that P-glycoprotein (P-gp) attenuates the central nervous system penetration and central activity of some opioids. The impact of P-gp-mediated efflux on the disposition and efficacy of the synthetic opioid alfentanil currently is unknown. In this study, P-gp-competent [mdr1a(+/+)] and P-gp-deficient [mdr1a(–/–)] mice were used to investigate the impact of P-gp-mediated efflux on the systemic pharmacokinetics, brain disposition, and central activity of alfentanil. Equipotent doses of alfentanil were administered to mdr1a(+/+) and mdr1a(–/–) mice (0.2 and 0.067 mg/kg, respectively), and the time course of brain and serum concentrations as well as antinociception were determined. A pharmacokinetic-pharmacodynamic (PK-PD) model was fit to the data and used to assess the impact of P-gp on parameters associated with alfentanil disposition and action. The mdr1a(+/+) mice were less sensitive to alfentanil than mdr1a(–/–) mice, requiring a 3-fold higher dose to produce similar antinociception. PK-PD modeling revealed no differences in alfentanil systemic pharmacokinetics between P-gp expressers and nonexpressers. However, the steady-state brain-to-serum concentration ratio (Kp,brain,ss) was ∼3-fold lower in mdr1a(+/+) mice compared with mdr1a(–/–) mice (0.19 ± 0.01 versus 0.54 ± 0.04, respectively). Consistent with the ∼3-fold lower Kp,brain,ss, the antinociception versus serum concentration relationship in mdr1a(+/+) mice was shifted ∼3-fold rightward compared with mdr1a(–/–) mice. However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC50 (11 ± 1.8 versus 9.2 ± 1.7 ng/g), between mdr1a(+/+) and mdr1a(–/–) mice. These results indicate that alfentanil is an in vivo P-gp substrate and are consistent with the hypothesis that P-gp-mediated efflux attenuates antinociception by reducing alfentanil Kp,brain,ss. The American Society for Pharmacology and Experimental Therapeutics